

➤ **2022**  
**Masterclass in**  
**Systemic**  
**Cancer Therapy**

“*Embracing the Essence  
of Cancer Therapeutics*”



(CPD points will be awarded)



**UNIVERSITY  
OF MALAYA**



**Malaysian Oncological  
Society**

Date : **30-31st July 2022**  
( 8 am - 5pm )

Email : [msctummc@gmail.com](mailto:msctummc@gmail.com)

Join us for a virtual conference with leading  
experts in cancer therapeutics.

[Click here to register](#)



# MESSAGE



## FROM HEAD OF DEPARTMENT

CLINICAL ONCOLOGY DEPARTMENT,  
UNIVERSITY MALAYA MEDICAL CENTRE

PROF DR HO GWO FUANG



“I would like to welcome each of you to the Materclass in Systemic Cancer Therapy (MSCT) for the year of 2022. The Department of Clinical Oncology of University Malaya, in collaboration with Malaysian Oncological Society (MOS), has collaborated for the sixth time to make this annual event possible. This program was specifically designed to enrich your knowledge on the basic Pharmacology underpinning cancer treatment. We hope that by attending this course, you will gain cutting edge and relevant information with which you can apply in your daily clinical practice. Thank you for your participation and please enjoy the course.”

# MESSAGE FROM CHAIRPERSON



MASTERCLASS IN SYSTEMIC CANCER THERAPY 2022



DR NISHA MOHD SHARIFF

"Hello everyone and welcome to the 6th Masterclass in Systemic Cancer Therapy. Due to the COVID-19 pandemic, we organised our first MSCT as a virtual event last year which was a huge success - with over 200 participants attending the event from all over Malaysia. Despite it being a virtual event, I hope that the participants are still able to interact with the committee and speakers throughout the course. I would like to thank the organizing committee and speakers for their hard work in the run up to the MSCT 2022. I am grateful for the ongoing support for this course over the years from all of you, as well as University Malaya, the Malaysian Oncological Society and sponsors. Finally, I hope everyone enjoy this educational weekend and see you online soon!"



## ORGANIZING COMMITTEE

Dr Nisha Mohd Sharif (Chairperson)

Dr Zulaikha Rozman

Dr Yong Chen Joyce

Ms Toh Yok Yong

Ms Christpine Menti Sarie

Dr Sanesh Ryann Jay Maganran

Dr Asyraf Muaadz Abd Kudus

Ms Ong Yi Theng (ROCHE)

Ms Shereen Hew (ROCHE)

Ms Grace Leong (ROCHE)

## SCIENTIFIC COMMITTEE

Prof. Ho Gwo Fuang

Prof. Anita Bustam

Prof. Adlinda Alip

Prof. Marniza Saad

Prof. Rozita Abdul Malik

Prof. Wan Zamaniah Wan Ishak

Dr. Nur Fadhlina Abdul Satar

Dr. Nisha Shariff

# Agenda




## Day 1 :30th July 2022 (SATURDAY)

Time	Topics	Speakers
0800-0805	Welcome address	Nisha Shariff Organising Chairperson MSCT
<b>Plenary 1</b>		
0805-0825	Drug Development and Clinical Trials in Cancer <b>SPONSORED BY FRESENIUS KABI</b>	Fuad Ismail Clinical Oncologist, Hospital Canselor Tuanku Muhriz UKM
0825-0850	The Pharmacological Aspect of Cytotoxics	Fuad Ismail Clinical Oncologist, Hospital Canselor Tuanku Muhriz UKM
0850-0905	Q&A	
0905-0920	BREAK	
<b>Plenary 2</b>		
0920-0945	Antimetabolites	Khairiyah Sidek Clinical Oncologist, Hospital Canselor Tuanku Muhriz UKM
0945-1010	Topoisomerase Inhibitors	Nur Ain binti Rosli Ahmad Abdullah Pharmacist, Hospital Tengku Ampuan Rahimah Klang
1010-1035	Platinum Agents	Loong Ly Sia Pharmacist, Hospital Canselor Tuanku Muhriz UKM
1035-1050	Q&A	
1050-1105	BREAK	


# Agenda

## Day 1 :30th July 2022 (SATURDAY)

### Plenary 3



1105-1130	Antimicrotubules	Carolyn Eng Chai Hui Pharmacist, University Malaya Medical Centre
1130-1155	Alkylating Agents	Tan Wen Chieh Pharmacist, University Malaya Medical Centre
1155-1220	Analgesics for Cancer Pain	Vaishnavi Jeyasingam Clinical Oncologist, Hospital Kuala Lumpur
1220-1240	Response Assessment of Systemic Cancer Therapy	Mohammad Nazri bin Md Shah Radiologist, University Malaya Medical Centre
1240-1255	Q&A	
1255-1350	 LUNCH TALK - SPONSORED BY ROCHE	

### Plenary 4

1350-1415 (25min)	Acute and Late Toxicity of Systemic Treatment	Muthukkumaran Thiagarajan Clinical Oncologist, Hospital Kuala Lumpur
1415-1440 	Supportive Treatment during Chemotherapy <b>SPONSORED BY TERAJU PHARMA</b>	Anna Lim Clinical Oncologist, Institut Kanser Negara
1440-1500 (20min)	Extravasation	Nur Shamelia Yahya Oncology Nurse, University Malaya Medical Centre


# Agenda

## Day 1 :30th July 2022 (SATURDAY)

1500-1515	Q&A	
1515-1530	BREAK	
Plenary 5		
1530-1555 	Endocrine Therapy in Male Cancers <b>SPONSORED BY DrReddy</b>	Sucharit Pongprakyun Clinical Oncologist, KPJ Sabah
1555-1620 	Endocrine Therapy in Female Cancers <b>SPONSORED BY ACCORD</b>	Marfu'ah Nik Eezamuddeen Clinical Oncologist, Hospital Canselor Tuanku Muhriz UKM
1620-1640 (20min)	Mechanism of Drug Resistance	Wong Yoke Fui Oncologist, Institut Kanser Negara
1640-1655	Q&A	
1655-1700	CLOSING	

## Day 2 : 31th July 2022 (SUNDAY)

### Plenary 6

0800-0820	Tailoring Treatment in Special Situations	David Lee Clinical Oncologist, National Cancer Center Singapore
0820-0840	Chemotherapy in Pregnancy and Medical Fertility Sparing Options	Dr Jennifer Leong Siew Mooi Clinical Oncologist, Sunway Medical Centre
0840-0900 	Personalized Medicine in Cancer Therapeutics: Past, Present and Future <b>SPONSORED BY MERCK</b>	Ho Kean Fatt Clinical Oncologist, Mt Miriam Cancer Hospital
0900-0915	Q&A	
0915-0930	BREAK	

### Plenary 7

0930-0955 	EGFR-targeted Therapy <b>SPONSORED BY BOEHRINGER INGELHEIM</b>	Dr Patricia Shamani Soosainathan Clinical Oncologist, Institut Kanser Negara
0955 -1020 	ALK/ROS-d1 Inhibitor Therapy <b>SPONSORED BY PFIZER</b>	Dr Soo Hoo Hwoei Fen Clinical Oncologist, Penang General Hospital



## Day 2 :31th July 2022 (SUNDAY)

### Plenary 7

1020-1045	VEGF and Multikinase Inhibitors <b>SPONSORED BY EISAI</b>	Tan Chih Kiang Clinical Oncologist, Thomson Hospital Kota Damansara
1045-1100	Q&A	
1100-1115	BREAK	

### Plenary 8

1115-1140	HER-2 Targeted Therapy <b>SPONSORED BY ROCHE</b>	Doris Chow Clinical Oncologist, Pantai Hospital Penang
1140-1205	CDK4/6, PIK3CAi, AKT and mTOR inhibitors	Nur Fadhlina Abdul Satar Clinical Oncologist, University Malaya Medical Centre
1205-1230	PARP inhibitors	Marniza Saad Clinical Oncologist, University Malaya Medical Centre
1230-1250	BRAF/MEK inhibitors	John Low Clinical Oncologist, Pantai Hospital Kuala Lumpur
1250-1305	Q&A	
1305-1400	<b>IPSEN</b> Innovation for patient care	<b>LUNCH TALK - SPONSORED BY IPSEN</b>

# Agenda

Day 2 :31th July 2022 (SUNDAY)

## Plenary 9

1400-1425  <b>IPSEN</b> Innovation for patient care	Somatostatin Targeted Therapy <b>SPONSORED BY IPSEN</b>	Wan Zamaniah Wan Ishak Clinical Oncologist, University Malaya Medical Centre
1425-1450	Immune - checkpoint Inhibitors and Toxicities	Voon Pei Jye Medical Oncologist, Sarawak General Hospital
1450-1515	Biosimilars : Development and Challenges	Chua Hui Ming Pharmacist, National Pharmaceutical Regulatory Agency
1515-1530	Q&A	
1530-1545	BREAK	
1545-1605	CAR T cell therapy	Gan Gin Gin Haematologist, University Malaya Medical Centre
1605-1630 	High Dose Chemotherapy <b>SPONSORED BY BECTON, DICKINSON AND COMPANY</b>	Bee Ping Chong Haematologist, University Malaya Medical Centre
1630-0645	Q&A	
1645-1710	QUIZ	
1710-1730	Closing	

# SPEAKERS PROFILE



**PROF DATO DR FUAD ISMAIL**  
Clinical Oncologist, UKM Medical Centre

Prof. Dato' Dr. Fuad Ismail obtained his medical degree from Universiti Kebangsaan Malaysia and completed oncology training in Glasgow, Scotland with the FRCR (UK) and the FFR (Ireland) in 1996. He has served as the Head of Department in UKM Medical Centre since 1999. He is both a teacher and an examiner for the Masters of Clinical Oncology program. He has worked on various projects with the International Atomic Energy Agency and Ministry of Health Malaysia. His research interests are namely breast, cervical and colorectal cancers, and is active as a clinical trialist in drug development. He has keen interest in value-based medicine and availability of new drugs for Malaysia.

Dr Khairiyah graduated from University of Malaya with a MBBS degree in 2007 then graduated with a Masters of Clinical Oncology degree in University of Malaya in 2017. She has been working in various hospitals before joining UiTM as a lecturer in 2010. She is currently working at Hospital Canselor Tuanku Muhriz as a Clinical Oncologist.



**DR KHAIRIYAH SIDEK**  
Clinical Oncologist, UKM Medical Centre



**MS NUR AIN BINTI  
ROSLI AHMAD ABDULLAH**

Brought up in a family of medicine field. She was always inspired by her late mother who had dedicated her whole life as an oncology nurse. She graduated from a local university with a Bachelor Degree of pharmacy (hons). Having a competitive character since young, she is always searching for challenges in clinical managements. Ms Nur Ain is a very dedicated and aspiring oncology pharmacist that also has a credentialing in parenteral nutrition in Malaysia for more than 8 years.

Oncology & Parenteral Pharmacist, Hospital Tengku  
Ampuan Rahimah, Klang

# SPEAKERS PROFILE



**MS LOONG LY SIA**

Pharmacist, UKM Medical Centre

Miss Loong is a senior pharmacist serving at UKM Medical Centre with 15 years of work experience as an inpatient pharmacist, clinical pharmacist to general medical units and currently to the hematology and bone marrow transplant units. She graduated with a Degree in Pharmacy (Hons) from University of Strathclyde (Glasgow) and later obtained a Masters in Clinical Pharmacy and Practice Policy (Distinction) from University College of London (UK) under a Commonwealth Scholarship. Her current work includes overseeing medication safety activities, monitoring of drug therapy, providing clinical drug information, patient education, developing protocols and policies. She also works as clinical tutor and sessional lecturer in UKM and other universities. She is also a member of Malaysian Pharmaceutical Society, American College of Clinical Pharmacy and also has been a speaker in various local and national symposiums.

Miss Carolyn graduated from Monash University (Aus) with a Bachelors degree in Pharmacy in 2012. She had exposure to the Australian Healthcare system through Professional Experience Placement, voluntary work, and part-time employment. She started her career at University Malaya Medical Centre in 2013 as a pre-registered pharmacist and was offered the Registered Pharmacist position in 2014. She worked as part of the outpatient pharmacy team in providing healthcare services to the public at the frontline in 2014. She is currently working in the Inpatient Pharmacy Chemotherapy (IPC) unit which provides clinical pharmacy services to the Oncology and Haematology units of UMMC.



**MS CAROLYN ENG CHAI HUI**

Pharmacist, University Malaya Medical Centre

Graduated from University Science Malaysia with Bachelor Degree in Pharmacy. Developed interest in Oncology Pharmacy since 2008. Then in 2015, took over Head of Manufacturing Section of Pharmacy Department which covers compounding of sterile & non sterile drugs services. Committee member for Asia Pacific Oncology Pharmacy Community (APOPC) representing Malaysia since December 2021. An ordinary member for International Society of Oncology Pharmacy Practitioner (ISOPP) since 2011.



**MR TAN WEN CHIEH**

Pharmacist, University Malaya Medical Centre

# SPEAKERS PROFILE



**DR VAISHNAVI JEYASINGAM**

Clinical Oncologist, Hospital Kuala Lumpur

Dr Vaishnavi Jeyasingam graduated with MBBS from University of Malaya, in 2005 and was awarded the Dean's List. She obtained her Masters in Clinical Oncology from the same institution and is currently a clinical oncologist at the Radiotherapy and Oncology Department in Hospital Kuala Lumpur with sessionals at Subang Jaya and Parkcity Medical Center. Dr Vaishnavi underwent a clinical attachment with the Head and Neck Radiation unit at the Princess Alexandra Hospital in Brisbane, Australia. She is a supervisor and external examiner of the Masters in Clinical Oncology programme, University Malaya. She is also part of the National Curriculum writing committee for Oncology.

Associate Prof Nazri obtained both his MBBS degree and Masters in Radiology from University of Malaya in 2004 and 2010 respectively. He serves as a Consultant Clinical Radiologist and Nuclear Medicine Specialist at the University of Malaya Medical Centre. His areas of interest are oncology PET-CT imaging, SPECT-CT radionuclide imaging, uro-radiology and colorectal radiology. He received the Excellent Service Award from the University of Malaya in 2016. He is active in both research and teaching and has had multiple scientific paper publications in reputable journals. He also serves as a thesis supervisor to post-graduate students in Radiology.



**ASSOC. PROF DR MOHAMAD  
NAZRI BIN MD SHAH**

Radiologist, University Malaya Medical Centre



**DR MUTHUKKUMARAN  
THIAGARAJAN**

Clinical Oncologist, Hospital Kuala Lumpur

Dr Muthukkumaran obtained his Masters in Clinical Oncology from Universiti Malaya in 2013. He previously served at Sabah Women and Children Hospital and is currently based at Hospital Kuala Lumpur's Department of Radiotherapy and Oncology. Dr Muthukkumaran has a special interest in pulmonary oncology, genitourinary oncology, neuro oncology (including stereotactic cranial radiosurgery) and paediatric radiation. He is currently the Honorary Secretary of Malaysian Oncological Society (MOS) and South East Asia Radiation Oncology Group (SEAROG). He is a national representative to the Federation of Asian Organizations for Radiation Oncology (FARO) and International Atomic Energy Agency (IAEA).

# SPEAKERS PROFILE



**DR ANNA LIM YI WAY**

Clinical Oncologist, Institut Kanser Negara

She obtained bachelor medical degree in University Putra Malaysia (UPM) in 2009 and completed postgraduate training in clinical oncology from University Malaya (UM) in 2019. She worked in Hospital Likas, Sabah from year 2020 till May 2022 and is currently a clinical oncologist in National Cancer Institute, Putrajaya.

She is now working at the Oncology Clinical Department. Her academic qualifications include Diploma In Nursing (2008) and Advanced in Oncology Care Nursing (2013). She previously served in the Haematology Ward from 2008 – 2019 and currently serves the Oncology Clinical Department from 2020 until now.



**MS NUR SHAMELIA  
BINTI YAHYA**

Oncology Nurse, University Malaya Medical Centre



**DR SUCHARIT PONGPRAKYUN**

Clinical Oncologist, KPJ Sabah

Dr. Sucharit Pongprakyun obtained his medical degree from Universiti Putra Malaysia (UPM) in 2004. He subsequently pursued a postgraduate degree in Clinical Oncology in Universiti Malaya (UM). He previously worked at the National Cancer Institute (IKN) and Nuclear Medicine & Radiotherapy Centre of Sabah Women and Children Hospital (Hospital Likas) in Kota Kinabalu, Sabah. He is currently working as a clinical oncologist in KPJ Sabah. He is actively involved in clinical trials and clinical teaching for medical officers. His area of interest includes head and neck, lung, breast and colorectal cancer.

# SPEAKERS PROFILE



Dr Marfu'ah graduated from University of Leicester, United Kingdom in 2007 and underwent her core medical specialist training in Warwickshire until 2011. Upon her return to Malaysia, she ventured into Oncology and obtained her Masters in Clinical Oncology in University Malaya in 2015. She was the Head of Oncology Unit, University Teknologi MARA until 2020. She currently practices in Hospital Canselor Tunku Mukhriz, PPUKM. She has a particular interest in thoracic, gynaecological, breast malignancies and palliative/supportive care.

**DR MARFU'AH NIK EEZAMUDDIEN**

Clinical Oncologist, UKM Medical Centre

Graduated as Doctor (MBBS) from University Malaya (UM) year 2005 and Master in Clinical Oncology (UM) year 2014. Working as Clinical Oncologist in Oncology in the Department of Oncology and Radiotherapy in Institut Kanser Negara (IKN) since 2014. She is the Head of Clinical Research Centre in IKN since 2016. She is also supervisor for Master Programme for Clinical Oncology. She was the previous member of the Clinical Practice Guideline for Nasopharyngeal Carcinoma in 2017. She has been involved as a principal investigator and co-investigator in clinical trials.



**DR WONG YOKE FUI**

Clinical Oncologist, Institut Kanser Negara



**DR DAVID LEE DAI WEE**

Clinical Oncologist, National Cancer Centre Singap

Dr David Lee is a Clinical Oncologist at University of Malaya Medical Centre and is currently pursuing a clinical fellowship in experimental therapeutics at National Cancer Centre Singapore. His key interests is in thoracic oncology and early phase clinical trials. Dr Lee is the inaugural ASCO (Asia Pacific) Leadership Development Program 2021-2022 participant.

# SPEAKERS PROFILE



**DR JENNIFER LEONG SIEW MOOI**

Clinical Oncologist, Sunway Medical Centre

Dr. Jennifer Leong Siew-Mooi graduated with Masters in Clinical Oncology from Universiti Malaya in 2015 and went to practice at the renowned National Cancer Institute up until 2020. She is currently a Consultant Clinical Oncologist at Sunway Medical Center. Dr. Leong is experienced in specialized radiotherapy planning technique such as intensity modulated training (IMRT), stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT) as well as image-guided 3D brachytherapy for gynecologic malignancies. She also offers advice on suitable systemic treatment such as systemic chemotherapy, targeted therapy and immunotherapy on various solid tumors. Her main interests lie in the management of breast, lung and gynecological malignancies. Dr. Leong currently holds an active position in the working committee for the latest update of National Breast Cancer Clinical Practice Guideline. Besides being a clinician, she is passionate in promoting patient advocacy and cancer awareness among the public.

Dr Ho started his medical education at the International Medical College (IMU), Kuala Lumpur and further his clinical training in Belfast, UK. After graduation from the Queen's University of Belfast in 1999, he continued his training as a physician and obtained his MRCP in 2002. He was accepted into the Clinical Oncology training based in Birmingham and after obtaining his FRCR, he took on a 2 year Fellowship in Head and Neck IMRT at the Christies, Manchester. In the 2 years as a Clinical Research Fellow, he contributed several research publications in peer-reviewed journals. He obtained his research Medical Doctorate (MD) in Head and Neck Advance Radiotherapy from the University of Manchester in 2009. After working for over 10 years in UK, he returned as a Consultant Clinical Oncologist at Mount Miriam Cancer Hospital in 2010.



**DR HO KEAN FATT**

Clinical Oncologist, Mt Miriam Cancer Hospital



**DR PATRICIA SHAMANI  
SOOSAINATHAN**

Clinical Oncologist, Institut Kanser Negara

Dr Patricia is currently attached to Institute Kanser Negara, IKN as a Clinical Oncologist. She attained her Masters in Clinical Oncology from University Malaya in 2020 and is currently involved in multiple current clinical trials as sub-investigator and is part of the team working on the Second Edition Cancer Pain CPG.



# SPEAKERS PROFILE



**DR SOO HOO HWOEI FEN**

Clinical Oncologist, Penang General Hospital

Dr Soo Hoo has worked as a Clinical Oncologist in Hospital Kuala Lumpur and Hospital Ipoh before current station in Hospital Pulau Pinang. Apart from being a clinician, she is involved with the post-graduate medical training as a trainer and is active in multiple clinical trials. She holds a FRCR(UK) qualification and was a recipient of Federal Government Public Service Scholarship for fellowship in The Christie NHS, Manchester, UK.

Dr Tan Chih Kiang is currently a Consultant Clinical Oncologist in Thomson Hospital. He obtained his medical degree from the International Medical University & went on to pursue a Master in Clinical Oncology from the University of Malaya. He has worked in several Ministry of Health (MOH) hospitals, with the National Cancer Institute being his most recent tenure prior to joining the private sector. He has participated in numerous international clinical trials with special interest in breast, lung, and hepatobiliary cancer; as well as spearheaded and be part of the organizing committees in various congresses.



**DR TAN CHIH KIANG**

Clinical Oncologist,  
Thomson Hospital Kota Damansara



**DR DORIS CHOW**

Clinical Oncologist, Pantai Hospital Penang

Dr Doris obtained her Fellowship of the Royal College of Radiologist in Clinical Oncology (FRCR) and was conferred the Rohan Williams Medal. This medal is awarded to an outstanding candidate at each sitting at the final examination from the fellowship. At the Christie, Dr Doris was trained in various cancer subsites and has experience with advanced radiotherapy techniques used for cancer management. Her interest is in neuro-oncology and particularly the use of stereotactic radiosurgery to treat benign and malignant central nervous system tumours (brain tumours). Dr Doris also has a keen interest in treating paediatrics brain/spine, lung cancer, thyroid cancer, head and neck cancers, skin cancer, breast cancer and upper and lower gastro intestinal cancers.

# SPEAKERS PROFILE



Dr Fadhlina is a consultant in clinical oncology at University Malaya Medical Centre, Kuala Lumpur. She graduated from University of Nottingham Medical School in 2006, and completed her MRCP in 2009. She was trained at University College London Hospital and Barts NHS Trust, and subsequently obtained FRCR and Masters in Clinical Oncology under Institute Cancer Research. She attained Certificate for Completion of Specialist Training (CCST) in 2017 from GMC (UK). Her interest in medical education has generated publication in Clinical Oncology journal, and web based learning tool on Royal College Radiologists' website. Her clinical areas of interests are head and neck, breast and gastrointestinal cancers.

## DR NUR FADHLINA ABDUL SATAR

Clinical Oncologist, University Malaya Medical Centre

Marniza Saad is a Clinical Oncologist at the Department of Clinical Oncology, University Malaya Medical Centre (UMMC), and an Associate Professor at Faculty of Medicine, University of Malaya (UM) Kuala Lumpur. After obtaining her Medical Degree from University of Wales College of Medicine, Cardiff in 1997, she underwent specialist training in Clinical Oncology at Velindre Cancer Centre, Cardiff UK and attained FRCR qualification in 2006. She was the Head of Department of Clinical Oncology UMMC from 2013 to 2015 and has been a trainer for the Master of Clinical Oncology programme at Universiti Malaya since 2006. She was inducted as a Member of College of Radiology, Academy of Medicine, Malaysia in 2009. Her areas of special interest include genitourinary cancer, sarcoma, breast and gastrointestinal cancers.



## ASSOC. PROF DR MARNIZA SAAD

Clinical Oncologist,  
University Malaya Medical Centre



## DR JOHN LOW

Clinical Oncologist,  
Pantai Hospital Kuala Lumpur

Dr John Low obtained his Medical degree (MBBS) from the National University of Singapore in 1996. He received his oncology training at the National Cancer Centre Singapore and the Royal Marsden Hospital, UK. He obtained his MRCP(UK) in 2001 and FRCR(Clinical Oncology) in 2003. He is a Fellow of the Royal College of Physicians of Glasgow (FRCP). He is currently Consultant Clinical Oncologist at Pantai Hospital KL and Sunway Medical Centre. Prior to this, Dr. Low was a Consultant Oncologist at the National Cancer Centre Singapore and Visiting Consultant to the KK Women's & Children's Hospital in Singapore. He was also clinical tutor with the Faculty of Medicine, National University of Singapore and the Faculty of Medical Sciences, Singapore Nanyang Polytechnic. Dr John Low is active both in clinical work as well as clinical research.

# SPEAKERS PROFILE



**ASSOC. PROF DR WAN ZAMANIAH  
WAN ISHAK**

Clinical Oncologist, University Malaya Medical Centre

Associate Prof. Dr. Wan Zamaniah is a Consultant Clinical Oncologist at the University Malaya Medical Centre and University Malaya Specialist Centre, Kuala Lumpur, Malaysia. She graduated from University of Malaya, Kuala Lumpur Malaysia with Bachelor of Medicine & Bachelor of Surgery. Upon completion of her specialist training in clinical oncology in 2010 at the University of Malaya she was awarded with the Master of Clinical Oncology, University of Malaya in 2010. Her areas of special interest include gastrointestinal cancers, head and neck cancers, gynaecological cancers, breast cancers and other solid tumours. She is principle investigator for several international clinical trials mainly in gastrointestinal cancers and head and neck cancers. She published some of her works in the areas involved. She speaks in her areas of interest in both local and international scientific conferences.



**DR VOON PEI JYE**

Medical Oncologist, Sarawak General Hospital

Dr Voon Pei Jye is the Head and Consultant Medical Oncologist, Hospital Umum Sarawak. He obtained his MRCP (UK) and MMed (Internal Medicine) from National University of Singapore. Subsequently, he received his advanced specialist training in Medical Oncology from National University Hospital Singapore. He has completed his Phase 1 Drug Development clinical research fellowship at Princess Margaret Cancer Centre, University of Toronto, Canada. He is an active investigator for numerous cancer trials and has published in various peer reviewed journals. He is a recipient for Hold'em for Life Oncology Fellowship Award, University of Toronto. He has won the Scholar Training Award from AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021.



**MS CHUA HUI MING**

Pharmacist,

National Pharmaceutical Regulatory Agency

Ms Hui Ming Chua obtained her Bachelor of Pharmacy degree from University of Malaya in Malaysia and served for the Ministry of Health Malaysia since 2005 in various departments. In 2013, she further pursued her master degree in King's College London and graduated from Master of Science in Pharmaceutical Technology within a year. She has been positioned in the Biologics Section of National Pharmaceutical Regulatory Agency (NPRA), under the Ministry of Health Malaysia since October 2014. She is responsible for regulatory review of biopharmaceutical products which include innovative biotechnology products, biosimilars, vaccines, blood products and other biotherapeutics.

# SPEAKERS PROFILE



**PROF DR GAN GIN GIN**

Haematologist, University Malaya Medical Centre

Prof Gan Gin Gin is currently a professor of Medicine at University Malaya Medical Centre (UMMC). She is currently the President of the Malaysian Society of Haematology and she holds many positions in the national committees and has co-authored several national guidelines. She has published numerous papers in peer-reviewed journals. She is involved in many international clinical trials and participates in international registry. Her major areas of expertise are general haematology, haematology-oncology and hematopoietic stem cell transplantation.


Prof Dr Bee is a Consultant Haematologist and a lecturer at the Faculty of Medicine, University of Malaya (UM) and the University of Malaya Medical Centre. He is a member of the Malaysian Medical Association, the Malaysian Society of Haematology and the European Society of Haematology. He has authored or co-authored many peer-reviewed journal articles and meeting abstracts in the field of Haematology. Assoc Prof Bee specialises in Haemato-Oncology (Myeloproliferative Disorders, Multiple Myeloma, Lymphomas, Leukaemias, myelodysplastic syndrome), non-Malignant Haematological disorders (bleeding disorders, Thrombosis and Anticoagulation, Anaemias, Idiopathic thrombocytopenic purpura, Haemoglobinopathy [Thalassaemia, Sickle Cell anaemia], paroxysmal nocturnal haemoglobinuria, thrombotic thrombocytopenic purpura) and haematopoietic stem cell transplantation/Bone marrow transplantation.



**PROF DR BEE PING CHONG**

Haematologist, University Malaya Medical Centre


**2022  
Masterclass in  
Systemic Cancer Therapy  
Lunch Talk**




## TOPIC

# Therapeutic Advances in Advanced Unresectable Hepatocellular Carcinoma: The Role of Immune Checkpoint Inhibitors

### Event Details:

 Saturday, 30th July 2022

 12.55 PM - 13.50 PM

 Virtual Conference



## SPEAKER

### Krittiya Korhaisarn, M.D.

Associate Professor, Division of Medical Oncology,  
Department of Medicine,  
Faculty of Medicine Siriraj Hospital,  
Mahidol University, Thailand.

2022 Masterclass in Systemic  
Cancer Therapy Lunch Talk

# Maximizing Efficacy And QoL

In Dynamic Era Of Advanced  
Renal Cell Carcinoma Management

31<sup>st</sup> July  
2022

1.05pm to 2.00pm



zoom

Platform: Fully virtual

International Speaker:



**Dr Cristina Suarez**  
Medical Oncologist  
Vall d'Hebron University Hospital

Chairperson and Moderator:



**A/Prof Adlinda Alip**  
Consultant Oncologist  
University Malaya Medical Centre

## Agenda

Time	Agenda	Session facilitate by
1.05pm – 1.10pm	Welcome & Introduction	A/Prof Adlinda Alip
1:10pm – 1.40pm	Maximizing Efficacy and QOL in dynamic era of advanced Renal Cell Carcinoma	Dr Cristina Suarez
1.40pm – 1:55pm	Practical approach to treating aRCC: Real-world cases	Dr Cristina Suarez
1.55pm – 2.00pm	Q&A	A/Prof Adlinda Alip Dr Cristina Suarez

# A Breakthrough In The Prevention And Treatment Of Radiation Dermatitis

# StrataXRT®

for the prevention and treatment of radiation dermatitis



## Consensus goals of care for skin reactions during radiation therapy<sup>1,2,3</sup>

## StrataXRT scores

01	Initial maintenance of skin integrity	✓
02	Reduced potential of further exacerbation of skin reactions	✓
03	Minimised water loss and optimised skin hydration by means of topical agents	✓
04	Promotion of comfort and compliance	✓
05	Reduction of pain and pruritus without causing a bolus effect	✓
06	Control of bleeding, odour and excessive exudate	✓ (in combination with secondary dressing)
07	Provides ideal environment for rapid re-epithelialisation	✓
08	Promotion of moist wound healing environment where skin is broken	✓
09	Protection from trauma and friction	✓
10	Protection from infection	✓



### StrataXRT 50g

Contains enough gel for over 5 weeks of treatment during a standard fractionation plan\* applying the gel twice per day.

\* Standard fractionation is considered to be 5 days per week. 2 weeks post radiation are expected for toxicity peak and 2 weeks more for recovery of the skin. The standard therapy time can therefore extend up to 2 weeks.

SKU available : **StrataXRT 20g**  
**StrataXRT 50g**

# www.strataxrt.com

**Ingredients:** Polydimethylsiloxanes, siloxanes, alkylmethyl silicones.

**References :** 1. Ho, AY, et al. (2018). Int J Radiat Oncol Biol Phys, 101, pp. 325–33. 2. Barnes, L., et al. (2015). Drug Saf, 38, pp. 493–509. 3. Boldeston, A., et al. (2006). Support Care Cancer, 14, pp. 802–817.

**Full prescribing information is available on request. Please consult full prescribing information before prescribing.**

Manufactured by:





Stratapharma AG,  
Aeschenvorstadt 57,  
CH-4051 Basel, Switzerland

Marketed by:



**Dr. Reddy's Laboratories Malaysia Sdn. Bhd.** (1238154-X)  
Unit 10-06, Level 10, Menara MBBM, No.1, Jalan Syed Putra,  
58000 Kuala Lumpur Malaysia.  
Tel: +603 2276 3229 Fax: +603 2276 3201 Email: info.mys@drreddys.com



# ZOMETA<sup>®</sup>

- ✓ Reduces Bone Recurrence
- ✓ Improves Disease Free Survival in the adjuvant breast cancer setting in women who are postmenopausal or have endocrine therapy-induced menopause.



**X3lifescience**  
Sdn Bhd (1195210T)

**ZOMETA<sup>®</sup>**  
zoledronic acid

(A Member of Teraju Pharma Group)

65-1, Jalan Setia Gemilang BG U13/13, Bandar Setia Alam, 40170 Shah Alam, Selangor, Malaysia. | T: +603 8071 5389

REFERENCE : Coleman R et al: Ann Oncol. 2020 Dec; 31(12):1650-1663



# THE NEXT LINE IS CLEAR

## NOW APPROVED

as monotherapy for the treatment of adult patients with ALK+ advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK TKI therapy; or crizotinib and at least one other ALK TKI

Rx LORVIQUA® 100 mg OD

### LORVIQUA®: A RECOMMENDED DOSING SCHEDULE OF 100MG ONCE DAILY<sup>1</sup>

Dose modifications can be used to manage adverse reactions associated with LORVIQUA®.<sup>1†</sup>



### LORVIQUA® OFFERS HOPE TO PATIENTS WHOSE DISEASE HAS PROGRESSED ON A SECOND-GENERATION ALK TKI<sup>1,2</sup>

LORVIQUA®	A potent third-generation ALK TKI designed to address the unmet medical needs of CNS progression and ALK resistance mutations <sup>2-4</sup>	LORVIQUA®	Demonstrated efficacy in patients whose disease has progressed on a second-generation ALK TKI <sup>2,4</sup>
LORVIQUA®	Manageable safety profile with a low discontinuation rate <sup>2,6</sup>	LORVIQUA®	Improved or stable QoL scores and symptoms, with protection against CNS progression <sup>5,6</sup>

### Consider prescribing LORVIQUA® as early as possible for your patients whose disease has progressed on a second-generation ALK TKI<sup>1,2</sup>

Cohort EXP3B: 1 prior second-generation ALK TKI (alectinib or ceritinib) ± CT. Cohorts EXP4-5: ≥2 prior ALK TKIs (crizotinib and at least one other ALK TKI) ± CT.<sup>7</sup>

\* Dose interruptions associated with TRAEs were reported in 83 patients (30%) and dose reductions due to TRAEs were reported in 61 patients (22%).<sup>7</sup>  
 † There are specific recommendations for dose modification related to the following adverse events: hyperlipidaemia, CNS effects, increased lipase/amylose, ILD/pneumonitis, AV block. Please refer to the LORVIQUA® Labeling Document, Therapy Management package (available from your representative), or medical information for dose recommendations for these adverse reactions.  
 ‡ ORR: 42.9% (95% CI: 24.5%–62.9%) (EXP3B, n=28); 33.6% (95% CI: 30.5%–49.4%) (EXP4-5, n=11). Intracranial ORR: 66.7% (95% CI: 29.9%–92.5%) (EXP3B, n=9); 52.1% (95% CI: 37.2%–66.7%) (EXP4-5, n=48).<sup>1</sup> Patients predominantly received either alectinib or ceritinib as the last ALK TKI before LORVIQUA® ± CT. Data cut-off: 2 February 2018.  
 § The most frequently reported TRAEs with LORVIQUA® include hypercholesterolaemia (81%), hypertriglyceridaemia (60%), oedema (43%) and peripheral neuropathy (30%), weight increase (18%), cognitive effects (18%) and mood effects (15%). Safety analysis set, N=275. Permanent discontinuations associated with TRAEs occurred in 7 patients (3%). Data cut-off: 15 March 2017.

LORVIQUA® is contraindicated in patients with a hypersensitivity to lorlatinib or any of the excipients of LORVIQUA® and in conjunction with concomitant use of strong CYP3A inducers. For special warnings and precautions for use, please see the LORVIQUA® Labeling Document.<sup>1</sup> ALK, anaplastic lymphoma kinase; AV, atrioventricular; CI, confidence interval; CNS, central nervous system; CT, chemotherapy; ILD, interstitial lung disease; NSCLC, non-small cell lung cancer; OD, once daily; ORR, objective response rate; Rx, prescribe; TKI, tyrosine kinase inhibitor; TRAE, treatment-related adverse event.

#### Lorviqua® Abbreviated Prescribing Information<sup>1</sup>

Lorviqua® (Lorlatinib) film-coated tablets, oral.  
**PRESENTATION:** Lorlatinib 25mg and 100mg film-coated tablets. Available in aluminum blister foil 3,6,9 or 12 blister strips with 10 tablets each for 25mg, and blister foil of 1 or 3 blister strip with 10 tablets for 100mg.  
**INDICATIONS AND USAGE:** Lorviqua® as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitors (TKI) therapy, or crizotinib and at least one other ALK TKI. This indication is approved under conditional registration which is based on tumor objective response rate and duration of response. Continued approval for this indication may be based on the outcome of clinical benefit in a confirmatory trial.  
**DOSE AND ADMINISTRATION:** 100 mg taken orally once daily continuously. Continue treatment as long as the patient is deriving clinical benefit from therapy. Lorviqua® may be taken with or without food.  
**CONTRAINDICATIONS:** Hypersensitivity to lorlatinib or to any of the excipients listed. Concomitant use of strong CYP3A inducers with lorlatinib is contraindicated due to the potential for serious hepatotoxicity (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] elevations).  
**WARNINGS AND PRECAUTIONS:** HYPERLIPIDAEMIA: The use of lorlatinib has been associated with increases in serum cholesterol and triglycerides. Serum cholesterol and triglycerides should be monitored before initiation of lorlatinib, 2, 4, and 8 weeks after initiating lorlatinib, and periodically thereafter. Initiation, or increase in the dose, of lipid-lowering agents is required. CENTRAL NERVOUS SYSTEM EFFECTS (CNS): CNS effects have been observed including psychotic effects, changes in cognitive function, mood, speech, and mental status changes. Dose modification or discontinuation may be required. ATROVENTRICULAR BLOCK: PR interval prolongation and atrioventricular (AV) block events have been reported. Monitor electrocardiogram (ECG) prior to initiating lorlatinib and monthly thereafter, particularly in patients with predisposing conditions to the occurrence of clinically significant cardiac events. Dose modification may be required. LEFT VENTRICULAR EJECTION FRACTION (LVEF) DECREASE: LVEF decrease has been reported in patients who had baseline and at least one follow-up LVEF assessment. In patients with cardiac risk factors and those with conditions that can affect LVEF, cardiac monitoring, including LVEF assessment at baseline and during treatment, should be considered. In patients who develop relevant cardiac signs/symptoms during treatment, cardiac monitoring, including LVEF assessment, should be considered. LIPASE AND AMYLASE INCREASE: Risk of pancreatitis should be considered. Patients should be monitored for lipase and amylase elevations prior to the start of lorlatinib treatment and regularly thereafter as clinically indicated. PNEUMONITIS: Severe or life-threatening pulmonary adverse reactions consistent with pneumonitis have occurred with lorlatinib. Lorlatinib should be withheld and/or permanently discontinued based on severity. HYPERTENSION: Blood pressure should be controlled prior to initiation of lorlatinib. Blood pressure should be monitored after 2 weeks and at least monthly thereafter during treatment with lorlatinib. Lorlatinib should be withheld and resumed at a reduced dose or permanently discontinued based on severity. HYPERGLYCAEMIA: Fasting serum glucose should be assessed prior to initiation of lorlatinib and monitored periodically thereafter. Lorlatinib should be withheld and resumed at a reduced dose or permanently discontinued based on severity. DRUG-DRUG INTERACTIONS: Concomitant use of any strong CYP3A inducer is contraindicated. Any strong CYP3A inducer should be discontinued for at least 3 plasma half-lives of the strong CYP3A inducer before lorlatinib treatment is started. FERTILITY AND PREGNANCY: Women of childbearing potential should be advised to avoid becoming pregnant while receiving Lorviqua®. A highly effective non-hormonal method of contraception is required for female patients because lorlatinib can render hormonal contraceptives ineffective. Male fertility may be compromised, and men should seek advice on effective fertility preservation before treatment. UNDESIRABLE EFFECTS: The very common (>1/10) and common (>1/10) adverse reactions of any grade reported in patients treated with Lorviqua® were anaemia, hypercholesterolaemia, hypertriglyceridaemia, mood effects, psychotic effects, mental status changes, cognitive effects, peripheral neuropathy, headache, speech effects, vision disorder, pneumonitis, diarrhoea, nausea, constipation, rash, arthralgia, myalgia, oedema, fatigue, weight increased, lipase increased, amylase increased.

APL-LORVIQUA®-021

Full prescribing information available upon request

References: 1. Lorlatinib (LORVIQUA®) Malaysia Labeling Document dated 2 February 2021. 2. Solomon BJ, Besse B, Bauer TM, et al. Lancet Oncol. 2018. doi: 10.1016/S1470-2045(18)30649-1. [Epub ahead of print]. 3. Johnson TW, Richardson PF, Bailey S, et al. J Med Chem. 2014;57(11):4720-44. 4. Gainor JF, Dardai L, Yoda S, et al. Cancer Discov. 2016;6(10):1119-33. 5. Peters S, et al. Lung Cancer. 2020;144:10-6. Bauer TM, et al. Targeted Oncology. 2020;15:55-65.



Pfizer (Malaysia) Sdn Bhd-197801003134 (40131-T)  
 Level 10 & 11, Wisma Avenir, Tower 2, AvenirHub 5, Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur.  
 Tel: 603-2281 6000 Fax: 603-2281 6388  
[www.pfizer.com.my](http://www.pfizer.com.my)

Date of preparation: April 2021  
 PP-LQA-MYS-0033-20APRIL2021



## Anti-EGFR agents are not the same<sup>6-8,16-20</sup>

### Experience

In addition to its wealth of evidence, Erbitux is supported by **over 15 years** of extensive clinical experience.<sup>20</sup>

**Over 615,000**  
patients treated with  
Erbitux for mCRC\*<sup>20</sup>



### Indication

**Only Erbitux** is also approved for treatment of locally advanced and recurrent and/or metastatic **head and neck cancer**<sup>16,17</sup>



Experts also state that Erbitux and panitumumab are **not the same**:



[Erbitux and panitumumab] are **distinct therapeutic agents** that should be considered individually during treatment planning. Available data for one agent can only partly be extrapolated to the other.

– Jesús García-Foncillas et al., 2019<sup>8</sup>



We can see that on one side both have common effects, but **cetuximab has additional immunologic effects**

– Dan Aderka,  
video interview, 2018



Clinical data for panitumumab in combination with chemotherapy is mostly limited to FOLFOX in the 1<sup>st</sup>-line setting, whereas **cetuximab has demonstrated efficacy and safety in Phase III 1<sup>st</sup>-line trials with both FOLFOX and FOLFIRI**

– Jesús García-Foncillas et al., 2019<sup>8</sup>



## A wealth of evidence and experience makes Erbitux the anti-EGFR agent of choice for 1<sup>st</sup>-line treatment of left-sided RAS wt mCRC

### References

1. Baran B, et al. Gastroenterology Res 2018;11:264–273
2. Arnold D, et al. Ann Oncol 2017;28:1713–1729
3. Holch JW, et al. Eur J Cancer 2017;70:87–98
4. Bokemeyer C, et al. Eur J Cancer 2012;48:1466–1475
5. Lenz H-J, et al. J Clin Oncol 2019;37:1876–1885
6. Monteverde M, et al. Crit Rev Oncol Hematol 2015;95:179–190
7. Lo Nigro C, et al. World J Gastrointest Oncol 2016;8:222–230
8. García-Foncillas J, et al. Frontiers Oncol 2019;9:1–16
9. Santini D, et al. Ann Oncol 2012;23:2313–2318
10. Cremolini C, et al. JAMA Oncol 2019;5:343–350
11. Aderka D, et al. Lancet Oncol 2019;20:e274–283
12. Wang ZX, et al. J Natl Compr Canc Netw 2019;17:805–811
13. Yoshino T, et al. Ann Oncol 2018;29:44–70
14. Venook A, et al. JAMA 2017;317:2392–2401
15. Heinemann V, et al. Lancet Oncol 2014;15:1065–1075
16. Erbitux Malaysia Product Information, April 2020
17. Panitumumab Malaysia Product Information, 2018
18. Petrelli F, et al. Oncology 2018;94:191–199
19. Patterson K, et al. ESMO 2019 (Abstract No. 596P)
20. Merck data on file, October 2019

\*Patient exposure data include patients treated in clinical trials and in the post-authorization setting.

**MERCK**

accord

The Evolution of Generics

**1st Generic  
Exemestane Tablets  
in Malaysia**



# SPONSORS



AstraZeneca Sdn Bhd (69730-X)



Specialised Therapeutics®

